Annual Congress on Diabetes and Endocrinology

Oct 26-27, 2020


Toronto, Canada

Diabetes & Endocrinology 2020 on October 26-27th, 2020 in Toronto, Canada 

About Conference

Endocrinology 2020 is going to be held on October 26-27, 2020 in Toronto, Canada. We cordially invite all the respected expertise, researchers, therapists, counselors, professors, students, business professionals, scientific communities, delegates, and executives to take part in our upcoming congress to witness invaluable scientific discussions and contribute to the future innovations in the field of  Diabetes & Endocrinology.

Endocrinology 2020 is a global platform to discuss and learn about Diabetes & Endocrinology as well as its related areas of healthcare which include overview, prevalence, trends and disparities, causes and its associated health problems and co-dependent relationship between Diabetes & Endocrinology. The upcoming conference will be organized around the theme “New Research on Endocrinology and Diabetic Disorders". Discussing various imperative topics will add an insight to contemplate and speak over the bottom line of today’s scientific and technological perk up. It will be an amazing opportunity for the attendees to explore the beautiful Toronto with gaining knowledge, sure to raise insights, amalgamate present with future and cogitate on ideas and reality at the conference. Endocrinology 2020 has taken this initiative to explore every aspect of Endocrinology & Advance Treatments.

Why to Attend???

This is your best opportunity to reach the largest assemblage of participants from the Diabetic and Endocrine Community. Live Events: which include Poster Presentations, Keynote Sessions, Video Presentations, Speaker Sessions providing a unique approach for healthy living, learning and career building. Attendees will be having an opportunity to build networks with experts in the field of Diabetes and Endocrinology, Business Delegates, Academics.

Conference Name



Endocrinology 2020

Toronto, Canada

October 26-27, 2020


Market Analysis

The global diabetes market is expected to increase at a CAGR of 7.6% percent for the predetermined period of 2018-2023. The market is segmented based on the type of diabetes, drug class, and diabetic devices. Diabetic drugs have the biggest market share amongst drugs and devices and are further expected to have the highest growth rate with a CAGR of 8.9%. Some of the top-selling diabetic drugs combine Lantus (Sanofi), Januvia (Merck And Co), Humalog (Eli Lily And Co), NoVo rapid (Novo Nordisk), Levemir (Novo Nordisk), Victoza (Novo Nordisk), Janumet (Merck And Co.), Novolog (Novo Nordisk), Humulin (Eli Lily And Co.) And Gallus (Novartis). With the diabetic population assumed to cross the 350 million market by 2030, the market is anticipated to show a strong growth rate. Diabetic drugs are highly-priced which could be one of the main disadvantages.

Growing incidences of endocrine dysfunctions such as hyperthyroidism and adrenal insufficiency is predicted to boost the demand for endocrine experiments. The growing diabetic, geriatric and obese population worldwide is expected to promote market growth. Furthermore, growing healthcare awareness among individuals joined with increasing government assistance is expected to increase the diagnosis at an early, thereby adding to the growth of the endocrine testing market. The major share in endocrine testing market share is held by companies such as Abbott Laboratories, AB Scitex, Agilent Technologies, Biomedical Technologies, Biomatrix SA, Bio-Rad Laboratories, Diasporic, Hoffmann-La Roche Ltd., LabCorp, and Quest Diagnostics.


Our Collaborations, Sponsors, Media Partners